Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Greg Yap
AddedMar 31, 2024
UpdatedMay 31, 2026
Greg Yap

Greg Yap

Board Member, BlueLight Therapeutics

CrunchbaseLinkedIn

Greg Yap's Career

BlueLight Therapeutics
BlueLight Therapeutics

Burlingame, CA, US

Board Member· Board
Particle Health
Particle Health

New York City, NY, US

Board Member· Board
Delfi Diagnostics
Delfi Diagnostics

Baltimore, MD, US

Board Member· Board
H1
H1

New York City, NY, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Greg Yap's Career

BlueLight Therapeutics
BlueLight Therapeutics
Series C$46.6M302000Burlingame, CA, US
Board Member· Board

Leadership at BlueLight Therapeutics

Joshua SalafskyJoshua SalafskyCo-Founder

Similar to BlueLight Therapeutics

MapLight TherapeuticsMapLight TherapeuticsPalo Alto, CA, USDrug Discovery, Therapeuticsest. 2018MapLight TherapeuticsPalo Alto, CA, US · est. 2018

Maplight: A biopharmaceutical firm innovating CNS disorder therapeutics via drug discovery platform.

Series C · $268.1M67
Ventus TherapeuticsVentus TherapeuticsWaltham, MA, USDrug Discoveryest. 2019Ventus TherapeuticsWaltham, MA, US · est. 2019

Ventus pioneers unique, structure-based drug discovery using our ReSOLVE™ platform, advancing new medicines for various diseases.

Angel · $370.1M96
Ensem TherapeuticsEnsem TherapeuticsMedford, MA, USDrug Discoveryest. 2021Ensem TherapeuticsMedford, MA, US · est. 2021

ENSEM Therapeutics: A biotech firm specializing in drug discovery and development for complex oncology targets.

Series A · $77M33
Bluejay TherapeuticsBluejay TherapeuticsSan Francisco, CA, USDrugs, Therapeuticsest. 2019Bluejay TherapeuticsSan Francisco, CA, US · est. 2019

Bluejay Therapeutics: A private biopharma firm developing innovative cures for infectious diseases.

Series B · $41M14
Particle Health
Particle Health
Series B$39.3M612019New York City, NY, US
Board Member· Board

Recent news

Finding CEO: It’s the new ‘Finding Nemo’TechCrunch · 2023

Leadership at Particle Health

Jason PrestinarioJason PrestinarioCEO
Troy BannisterTroy BannisterFounder

Similar to Particle Health

MetriportMetriportSan Francisco, CA, USAPI, Medical Dataest. 2022MetriportSan Francisco, CA, US · est. 2022

Metriport: Open-source API for seamless healthcare data integration and management.

Seed · $2.9M7
1upHealth1upHealthBoston, MA, USAPI, Healthcareest. 20171upHealthBoston, MA, US · est. 2017

1UpHealth, Inc. provides a healthcare API platform for aggregating and sharing health data across the US.

Series C · $75.5M165
Ribbon HealthRibbon HealthNew York City, NY, USAPI, Healthcare Dataest. 2016Ribbon HealthNew York City, NY, US · est. 2016

Healthcare data platform streamlining care decisions, provider info, and costs.

Acquired · $53.9M
PatientBankPatientBankSan Francisco, CA, USData Sharing, Medical Recordsest. 2015PatientBankSan Francisco, CA, US · est. 2015

PatientBank: Online platform for easy access & sharing of medical records.

Seed · $120k
Delfi Diagnostics
Delfi Diagnostics
Series B$330.5M2352019Baltimore, MD, US
Board Member· Board

Leadership at Delfi Diagnostics

Nicholas DracopoliNicholas DracopoliCo-Founder
Victor VelculescuVictor VelculescuCo-Founder & CEO
Robert B. ScharpfRobert B. ScharpfCo-Founder
Alessandro LealAlessandro LealCo-Founder

Similar to Delfi Diagnostics

Delphi DiagnosticsDelphi DiagnosticsAustin, TX, USCancer Diagnosticsest. 2016Delphi DiagnosticsAustin, TX, US · est. 2016

Delphi Diagnostics: Advancing endocrine therapy with gene expression algorithms for breast cancer.

Series A · $470k8
FreenomeFreenomeSouth San Francisco, CA, USCancer Detectionest. 2014FreenomeSouth San Francisco, CA, US · est. 2014

Freenome, a US-based company, is dedicated to providing tools for cancer detection, treatment, and prevention.

Late Stage Private · $1.1B375
Cleveland DiagnosticsCleveland DiagnosticsCleveland, OH, USCancer Diagnosticsest. 2013Cleveland DiagnosticsCleveland, OH, US · est. 2013

Cleveland Diagnostics: Innovating high-sensitivity cancer detection for early, curable stages.

Late Stage Private · $111M48
Helio HealthHelio HealthIrvine, CA, USCancer Detectionest. 2014Helio HealthIrvine, CA, US · est. 2014

Helio Health: AI-driven healthcare firm commercializing early cancer detection through simple blood tests.

Series B · $148M75
H1
H1
Series A$203.9M3752017New York City, NY, US
Board Member· Board

Leadership at H1

Ariel KatzAriel KatzFounder
Zachary FeuersteinZachary FeuersteinCo-Founder
Sylvie VeilleuxSylvie VeilleuxBoard Member
Ian SaxIan SaxFounder
Somesh DashSomesh DashBoard Member

Similar to H1

hc1.comhc1.comIndianapolis, IN, USHealthcare Platformest. 2011hc1.comIndianapolis, IN, US · est. 2011

hc1: A leading cloud-based platform personalizing healthcare and minimizing waste.

Seed · $49.3M172
FreshpaintFreshpaintWoerden, Utrecht, NLData Platform, Healthcareest. 2019FreshpaintWoerden, Utrecht, NL · est. 2019

HIPAA-compliant data handling for healthcare marketing.

Series A · $16.1M45
Heads Up HealthHeads Up HealthScottsdale, AZ, USAnalytics, Health Dataest. 2014Heads Up HealthScottsdale, AZ, US · est. 2014

Data analytics platform providing customizable health dashboards for individuals and healthcare professionals.

Seed · $3.1M42
ImpiricusImpiricusAtlanta, GA, USHealthcare, Platformest. 2021ImpiricusAtlanta, GA, US · est. 2021

Digital tool provider connecting physicians with the industry network.

Seed · $3.5M19

Greg Yap's Similar Executives & Operators

Nugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance Retail

People Similar to Greg Yap

Tyler SosinTyler SosinBoard Member · BluevineTim TullyTim TullyBoard Member · SquintNaomi Pilosof IonitaNaomi Pilosof IonitaBoard Member · EndgameSteve SloaneSteve SloaneBoard Member · EnableJohn EltonJohn EltonBoard Member · Rapid RoboticsMike VernalMike VernalGeneral Partner · Conviction Partners